ZVSA — Zyversa Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $3.14m
- $1.11m
- 18
- 52
- 13
- 17
Annual cashflow statement for Zyversa Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS/A | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -12.7 | -8.08 | -14.1 | -98.3 |
| Depreciation | ||||
| Deferred Taxes | ||||
| Non-Cash Items | 4.45 | 4.02 | 4.31 | 96.4 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | 3.11 | -1.02 | 5.66 | 2.6 |
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Cash from Operating Activities | -5.11 | -5.08 | -4.89 | -8.72 |
| Financing Cash Flow Items | -0.142 | 0 | -0.099 | -2.42 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 4.56 | 5.23 | 1.87 | 5.96 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | -0.55 | 0.154 | -3.02 | -2.76 |